Drug Trial Radar · NCT05754957
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
Last checked: Nov 20, 2026Latest source record: Jul 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
14,194
Actual
Start
Apr 7, 2023
Primary completion
Feb 6, 2026
Study completion Feb 6, 2026
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- Collaborators
- Bristol-Myers Squibb
- First posted
- Mar 6, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major adverse cardiovascular event (MACE) (the composite of cardiovascular \[CV\] death, myocardial infarction \[MI\], and ischemic stroke).
Conditions
- Acute Coronary Syndrome
Interventions
MilvexianDrug
Milvexian will be administered orally.
PlaceboOther
Placebo will be administered orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to First Occurrence of Major Adverse Cardiovascular Event (MACE)Time frame: Up to 3 years 6 months
Locations
1,003 sites in 44 countries. Site status is shown where the registry gives one.
Advanced Cardiovascular, LLC
Alexander City, Alabama
SORRA Research
Birmingham, Alabama
Ascension St. Vincent's Health System
Birmingham, Alabama
IMC-Diagnostic and Medical Clinic
Mobile, Alabama
Cardiology Associates of Mobile Inc
Mobile, Alabama
Mercy Gilbert Medical Center
Gilbert, Arizona
Valleywise Health Medical Center
Phoenix, Arizona
HonorHealth Neurology
Scottsdale, Arizona
Arkansas Heart Hospital
Little Rock, Arkansas
Bakersfield Memorial Hospital
Bakersfield, California
Mission Cardiovascular Research Institute
Fremont, California
Radin Cardiovascular Medical Group
Newport Beach, California
Valley Clinical Trials, Inc.
Northridge, California
Stanford University School of Medicine
Palo Alto, California
VA Palo Alto Healthcare System
Palo Alto, California
Huntington Hospital
Pasadena, California
The Cardiovascular Center
Redding, California
University Of California San Diego
San Diego, California
San Diego Cardiac Center
San Diego, California
VA San Diego Health Care System
San Diego, California
UCLA
Santa Monica, California
NorthBay Clinical Research, LLC
Santa Rosa, California
Ramin Manshadi, MD
Stockton, California
South Denver Cardiology Associates PC
Littleton, Colorado
Nuvance Health Medical Practices Cardiology Danbury
Danbury, Connecticut
Cardiology Associates of Fairfield County, P.C.
Stamford, Connecticut
George Washington University Medical Center
Washington D.C., District of Columbia
FWD Clinical Research
Boca Raton, Florida
Clearwater Cardiovascular Consultants
Clearwater, Florida
Holy Cross Hospital Inc.
Fort Lauderdale, Florida
Integrative Research Associates
Fort Lauderdale, Florida
University of Florida Health Jacksonville
Gainesville, Florida
Inpatient Research Clinic LLC
Hialeah, Florida
Shands Jacksonville Medical Center Inc dba UF Health Jacksonville
Jacksonville, Florida
Cardiology Partners Clinical Research Institute
Loxahatchee Groves, Florida
Baptist Hospital of Miami
Miami, Florida
Advanced Research for Health Improvement
Naples, Florida
Amavita Clinical Research (Dr. Pedro Martinez-Clark)
North Miami Beach, Florida
South Florida Research Solutions LLC
Pembroke Pines, Florida
Coastal Cardiology Consultants
Safety Harbor, Florida
Showing 40 of 1,003 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.